EBC-46

Propagation Techniques for Fontainea picrosperma: Seed Germination, Grafting, and Clonal Methods

Scaling tigilanol tiglate production depends on reliably propagating Fontainea picrosperma through seed germination, vegetative grafting, and emerging clonal techniques.

EBC-46

Adverse Event Profiles in Tigilanol Tiglate Trials: Local Tissue Response, Pain Management, and Recovery

Clinical trial data reveals a consistent pattern of local adverse events following tigilanol tiglate injection, including pain, swelling, and wound formation that resolve over weeks.

EBC-46

Calcium Signalling and PKC Activation: How EBC-46 Triggers Rapid Intracellular Calcium Flux

PKC activation by EBC-46 initiates a rapid calcium signalling cascade that contributes to tumour cell death, immune recruitment, and vascular disruption at the injection site.

EBC-46

GMP Manufacturing Requirements for Tigilanol Tiglate: What Pharmaceutical-Grade EBC-46 Production Demands

Good Manufacturing Practice standards govern how tigilanol tiglate must be produced, tested, and released before it can enter human clinical trials or reach the market.

Consumer Reports

Joint Pain, Mobility, and Blushwood Berry Extract: What Users Are Saying in 2026

A growing number of blushwood berry extract users are reporting improvements in joint pain and mobility, adding to an evolving body of consumer-reported outcomes.

Natural Source

Soil Mycorrhizae and Fontainea picrosperma: The Underground Network Behind Blushwood Berry Chemistry

The mycorrhizal fungi associated with Fontainea picrosperma roots may play an underappreciated role in the biosynthesis and concentration of tigilanol tiglate in blushwood fruit.

Human Trials

Wound Healing After Intratumoral EBC-46 Injection: What Phase I Data Reveals

Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.

Mechanism of Action

Neutrophil Recruitment and Tumour Clearance: The Innate Immune Response to EBC-46

EBC-46 triggers rapid neutrophil infiltration at the injection site, creating a localised inflammatory response that accelerates tumour clearance within hours.

Regulatory

FDA Botanical Drug Pathway: How IND Applications Shape the Future of EBC-46

The FDA botanical drug pathway offers a unique regulatory route for plant-derived compounds like EBC-46, with specific IND requirements that differ from synthetic drugs.

consumer-reports

Warts, Cysts, and Benign Growths: What Blushwood Berry Extract Users Self-Report as Targets

Blushwood berry extract users increasingly report applying it to warts, sebaceous cysts, and skin tags. Here's what those reports show, and where the science is plausible versus speculative.

natural-source

Biosynthesis of Tigilanol Tiglate: The Enzymatic Pathway Inside Fontainea picrosperma

The blushwood tree doesn't just produce tigilanol tiglate — it manufactures it through a complex series of enzymatic steps. Here's what science knows about that biosynthetic pathway.

human-trials

Complete Response vs Partial Response in EBC-46 Trials: How Clinical Researchers Define and Measure Success

How do EBC-46 trial investigators decide whether a treatment worked? The answer lies in RECIST 1.1 criteria and the specific challenges of measuring response in intratumoral therapy.